Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triamcinolone acetonide injectable suspension - Novartis

Next Previous
Drug Profile

Triamcinolone acetonide injectable suspension - Novartis

Alternative Names: Triesence

Latest Information Update: 09 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon
  • Developer Novartis
  • Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation

Most Recent Events

  • 24 Mar 2025 The Centers for Medicare & Medicaid Services (CMS) approves the issuance of a permanent, product-specific J-Code (J3300) for TRIESENCE, facilitating reimbursement and access in eyecare professionals’ offices
  • 11 Mar 2025 Harrow announces intention to submit a new drug application (NDA) to the US FDA for a next-generation version of TRIESENCE before the end of 2027
  • 04 Oct 2024 Harrow relaunches Triamcinolone acetonide injectable suspension for Ocular inflammation in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top